Trevi Therapeutics, Inc.

TRVI

$14.46

Updated: 23/09/2026, 22:58:28

Market Cap

$2.05B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for TRVI

Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

USD

NASDAQ

CEO: Jennifer L. Good

Employees: 34

https://www.trevitherapeutics.com

Asset Summaries

Latest generated summaries for TRVI

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for TRVI.

Share price: $14.46
Market cap: $2.05B
Exchange: NASDAQ
Currency: USD
CEO: Jennifer L. Good
Employees: 34
IPO date: 07/05/2019
Beta: 1.046
Last dividend: $0.00
Day range: $14.41 – $15.20
52-week range: $8.24 – $20.22
1-day performance: -5.12%
1-year performance: 75.49%
Current drawdown (1Y): -28.49%
CIK: 0001563880
CUSIP: 89532M101
ISIN: US89532M1018
Created: 07/12/2025, 14:47:41
Last update: 23/09/2026, 22:58:28

Track Trevi Therapeutics, Inc. with an AI analyst

See which prediction-market events move TRVI, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to TRVI from your Railway `news_articles` table.

Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Seeking Alpha • STOCK • 13/05/2026, 00:10:55

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

MarketBeat • STOCK • 09/05/2026, 07:07:16

Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 06/05/2026, 08:01:51

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewsWire • STOCK • 20/04/2026, 18:05:00

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

GlobeNewsWire • STOCK • 17/04/2026, 00:42:00

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewsWire • STOCK • 16/04/2026, 18:08:00

Trevi Therapeutics to Participate in Upcoming Events

GlobeNewsWire • STOCK • 01/04/2026, 09:30:00

Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 18/03/2026, 04:02:18

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

GlobeNewsWire • STOCK • 09/03/2026, 08:30:00

Trevi Therapeutics to Participate in Upcoming March Conferences

GlobeNewsWire • STOCK • 02/03/2026, 08:30:00

Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?

Zacks Investment Research • STOCK • 23/02/2026, 11:55:20